Q-omics provides the consensus-scored TRIM26 profile across patient tissues and cancer cell-line models. TRIM26 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRIM26 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TRIM26 RNA expression shows 19,973 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, THCA, and ACC as cancer lineages where TRIM26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM26 survival associations across molecular data types. TRIM26 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM26 RNA expression–survival associations across cancer types. High TRIM26 expression shows unfavorable associations in ACC and LGG, but favorable associations in BLCA, KIRC, MESO and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRIM26 RNA expression.
This table summarizes TRIM26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM26 shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, LIHC, BRCA and HNSC. The THCA box plot shows higher TRIM26 RNA expression in normal versus tumor tissue (log2 FC = −0.788, t-test p < 0.001).
This table shows molecular features associated with TRIM26 in patient tissues and cancer cell lines. In patient samples, TRIM26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
